ELOX
ELOX clinical trials: Eloxx Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Eloxx Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 9
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ELOX on the catalyst calendar · ELOX registry changes
- Primary completion Jun 30, 2027Sponsor estimatePhase 2NCT07523581EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and SafetyEloxx Pharmaceuticals, Inc. · Alport Syndrome, X-LinkedRecruitingELOXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2023ActualPhase 2NCT05448755A Study of ELX-02 in Patients With Alport SyndromeEloxx Pharmaceuticals, Inc. · Alport SyndromeCompletedELOXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 6, 2022ActualPhase 2NCT04126473A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleEloxx Pharmaceuticals, Inc. · Cystic FibrosisCompletedELOXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2017ActualPhase 1NCT03292302Phase 1 Study of ELX-02 in Healthy AdultsEloxx Pharmaceuticals, Inc. · Genetic DiseaseCompletedELOXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 3, 2022ActualPhase 2NCT04135495A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X AlleleEloxx Pharmaceuticals, Inc. · Cystic FibrosisCompletedELOXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2019ActualPhase 1NCT03776539A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02Eloxx Pharmaceuticals, Inc. · Impaired Renal FunctionCompletedELOXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2019ActualPhase 1NCT03309605Phase 1 Study of ELX-02 in Healthy Adult SubjectsEloxx Pharmaceuticals, Inc. · Genetic DiseaseCompletedELOXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2019ActualPhase 2NCT04069260A Phase 2 Study of ELX-02 in Patients With Nephropathic CystinosisEloxx Pharmaceuticals, Inc. · Genetic DiseaseTerminatedELOXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2017ActualPhase 1NCT02807961Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult VolunteersEloxx Pharmaceuticals, Inc. · Genetic DiseasesTerminatedELOXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner